Download PDF
Previous article
Go back to website
Next article
If you have problems to see the content please click here
Other users also viewed these articles
One-year retention rate of ixekizumab in patients with psoriatic arthritis and axial spondyloarthritis: Real-world data from the BIOBADASER registry
Clementina López-Medina; Lucía Otero-Varela; Fernando Sánchez-Alonso; Vega Jovaní; Lorena Expósito-Pérez; Sheila Melchor-Díaz; Yanira Pérez-Vera; Paula Pretel-Ruiz; Javier Manero; Antonio Mera-Varela; Lourdes Mateo; Dolores Ruiz-Montesino; José Andrés Lorenzo-Martín; Teresa Pedraz-Penalva; Isabel Castrejón;
Reumatol Clin. 2025;21:
Epidemiological characteristics and adverse events of patients with psoriatic arthritis undergoing treatment with biological therapies in Galicia
Carlos García Porrúa; Francisco José Maceiras Pan; José Antonio Mosquera Martínez; Loreto Carmona; Blanca Correa Rey; Luis Fernández Domínguez; María Noelia Álvarez Rivas; José Antonio Pinto Tasende;
Reumatol Clin. 2021;17:150-4
The activity of psoriatic arthritis with axial involvement correlates with the PsAID12
Jose Antonio Pinto Tasende; Carlota Laura Iñiguez Ubiaga; Victor Eliseo Quevedo Vila; Luis Fernández Dominguez; Francisco Jose Maceiras Pan; Carlos García Porrúa;
Reumatol Clin. 2024;20:80-3